Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_4
1
33%
Ph phase_2
1
33%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(2)
Other(1)

Detailed Status

Withdrawn2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

unknown133%
withdrawn267%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_4

Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19

NCT04715295
withdrawnphase_3

Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients

NCT04371406
withdrawnphase_2

HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19

NCT04575558

Clinical Trials (3)

Showing 3 of 3 trials
NCT04715295Phase 4

Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19

Unknown
NCT04371406Phase 3

Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients

Withdrawn
NCT04575558Phase 2

HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
COMBINATION PRODUCT
Total Trials
3